Russia has developed a groundbreaking mRNA-based cancer vaccine, set to be publicly available in early 2025. The vaccine, which will be distributed free of charge, targets specific cancer antigens to offer personalized treatment options Pre-clinical trials have shown promising results in suppressing tumor growth and preventing metastases. The vaccine leverages mRNA technology, similar to COVID-19 vaccines, to train the immune system to recognize and attack cancer cells.